KalVista Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	FY	FY	FY	FY	FY
Period Ending	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Selling, General & Admin	116.29	54.28	30.6	26.45	16.64
Research & Development	71.71	86.17	80.28	70.17	41.29
Total Operating Expenses	188	140.45	110.87	96.61	57.92
Operating Income	-188	-140.45	-110.87	-96.61	-57.92
Interest Income	6.44	3.9	2.23	1.09	0.9
Interest Expense	-5.79	-	-	-	-
Other Non-Operating Income (Expense)	7.29	9.91	15.73	13.18	10.78
Total Non-Operating Income (Expense)	7.94	13.8	17.96	14.27	11.68
Pretax Income	-180.05	-126.64	-92.91	-82.34	-46.24
Provision for Income Taxes	3.39	-	-	-	-
Net Income	-183.44	-126.64	-92.91	-82.34	-46.24
Net Income to Common	-183.44	-126.64	-92.91	-82.34	-46.24
Shares Outstanding (Basic)	50	37	28	24	19
Shares Outstanding (Diluted)	50	37	28	24	19
Shares Change (YoY)	34.98%	31.89%	13.96%	28.17%	7.58%
EPS (Basic)	-3.69	-3.44	-3.33	-3.36	-2.42
EPS (Diluted)	-3.69	-3.44	-3.33	-3.36	-2.42
Free Cash Flow	-153.34	-89.27	-76.46	-79.07	-30.25
Free Cash Flow Per Share	-3.09	-2.43	-2.74	-3.23	-1.58
EBITDA	-187.05	-139.63	-110.15	-96.05	-57.39
EBIT	-188	-140.45	-110.87	-96.61	-57.92
Effective Tax Rate	-1.88%	0.00%	0.00%	0.00%	0.00%

Updated Sep 11, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q